Agilon Health, Inc. (NYSE: AGL) – Investigated by Federman & Sherwood
January 15, 2026– The law firm of Federman & Sherwood, a national plaintiffs’ litigation firm representing shareholders and investors in complex securities matters, today announced that it has commenced an independent investigation into potential securities law violations by Agilon Health, Inc. (“Agilon” or the “Company”) (NYSE: AGL) on behalf of purchasers of the Company’s common stock.
Details of the Investigation:
Federman & Sherwood’s investigation focuses on whether Agilon and certain of its officers and directors made materially false or misleading statements or failed to disclose material information to investors regarding the Company’s business, financial condition, and prospects.
The investigation will examine whether Agilon misrepresented the Company’s visibility into key operational and cost trends, including the Company’s exposure to increased medical costs associated with its Medicare Advantage patient population and the adequacy of its accounting reserves to cover such costs. The investigation also will review whether the Company made overly optimistic public statements about its business model and future financial performance, and whether such statements might have concealed or contradicted known adverse facts.
In addition, the investigation will assess whether Agilon timely and accurately disclosed changes in leadership and financial guidance, including decisions to withdraw previously issued full-year earnings forecasts, and whether any such disclosures impacted the trading price of the Company’s securities.
As a result of these alleged misstatements and omissions, it is further alleged that investors may have suffered financial losses when corrective information came to light.
Background:
Agilon Health, Inc. is a healthcare company engaged in value-based care arrangements with physician partners, particularly in connection with Medicare Advantage plans. The Company’s common stock is publicly traded, and in recent years Agilon has issued statements concerning its operating performance, cost management, and growth prospects. Recent developments reported by investors and in public filings have raised questions regarding whether the Company fully and accurately informed the market of material business risks and evolving cost pressures.
What This Means for Investors:
Investors who purchased or otherwise acquired Agilon Health, Inc. common stock and suffered financial losses may contact Federman & Sherwood for a free and confidential consultation. The firm is evaluating potential legal claims and all available remedies on behalf of affected shareholders.
CONTACT FEDERMAN & SHERWOOD
Attorney Sara Collier is widely regarded as a leading attorney in the field of derivative shareholder litigation. She is driven by a deep commitment to ensuring that boards of directors and corporate executives of publicly traded companies answer to the shareholders they serve.
With over ten years of experience pursuing derivative cases nationwide—particularly in Delaware, the home jurisdiction for many major corporations—Ms. Collier has developed a reputation for skillfully pushing even the largest companies toward stronger transparency and accountability in their corporate governance.
Phone: (405) 235-1560
Email : sec@federmanlaw.com
*This is for information purposes and is not a solicitation.